Isis Announces That OGX-011 Has Shown Overall Survival Advantage In Prostate Cancer Compared To Standard Therapy In A Randomized Phase 2 Study Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that OncoGenex Pharmaceuticals, Inc. provided positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm") compared to docetaxel and prednisone alone ("the control arm") for first-line treatment of metastatic castrate resistant prostate cancer. The current 10.
Source: www.medicalnewstoday.comDrug Marketing Techniques May Be Risking Patient Safety, British Medical Journal With new
drugs being reviewed by regulatory agencies and then released onto the market faster than ever before, patients' safety is being compromised, warns a study published on bmj.com today.
Source: www.medicalnewstoday.com
# posted by Network @ 7:00 AM
